Breast, Prostate Imaging Regimens Would Be Aided By GEMS/Genometrix
This article was originally published in The Gray Sheet
Executive Summary
GE Medical Systems will combine its molecular diagnostic imaging platform with Genometrix' microarray gene and protein analysis technology to develop biomarkers for breast and prostate cancer.
You may also be interested in...
Third Wave Technologies IPO Will Fund Diagnostic Genotyping Tests
Third Wave Technologies intends to develop clinical diagnostic tests for several inherited and infectious diseases, the firm said in its July 31 prospectus detailing a $100 mil. initial public offering.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.